-+ 0.00%
-+ 0.00%
-+ 0.00%

ASAHI KASEI THERAPEUTICS ANNOUNCES FDA APPROVAL OF HOVILPRI® (PRITELIVIR) TABLETS FOR MUCOCUTANEOUS HSV LESIONS REFRACTORY (WITH OR WITHOUT RESISTANCE) TO STANDARD ANTIVIRAL TREATMENT IN IMMUNOCOMPROMISED ADULTS

Reuters·10/09/2026 22:41:00

Please log in to view news